| Marc Hutton | |
|---|---|
| Photo placeholder | |
| Affiliations | University College London Mayo Clinic Florida |
| Country | UK/USA |
| H-index | 150+ |
| ORCID | 0000-0002-6324-5041 |
| Research Focus | Alzheimer's Disease, FTD, Parkinson's Disease |
| Mechanisms | Tau, Genetics, MAPT |
Marc Hutton is a distinguished researcher in neurodegenerative diseases, with major contributions to understanding the genetics of Alzheimer's disease, frontotemporal dementia, and Parkinson's disease. His work has been instrumental in identifying key genetic risk factors and mutations that contribute to these conditions.
Hutton's most significant contribution was the identification of mutations in the MAPT gene (Microtubule-Associated Protein Tau) that cause familial frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17). This discovery established that tau dysfunction is sufficient to cause neurodegeneration, directly linking tau pathology to disease pathogenesis.
The identification of MAPT mutations provided critical evidence for the tau hypothesis of neurodegeneration and opened new avenues for therapeutic development targeting tau. His work demonstrated:
Beyond rare mutations, Hutton's work established the role of common MAPT haplotypes (H1 and H2) as risk factors for neurodegenerative diseases. The H1 haplotype has been associated with:
Hutton has also contributed significantly to understanding the genetics of Alzheimer's disease, including work on:
Hutton's research combines:
A central focus of Hutton's work has been understanding how tau mutations lead to neurodegeneration:
Hutton has contributed to understanding both rare mutations and common variants:
The genetic discoveries have direct implications for drug development:
Primary institutional affiliations:
This dual affiliation allows Hutton to maintain collaborations in both the UK and US, bridging European and American research communities in neurodegenerative disease genetics.